Physician profile
Jonathan Vivek Sukumar
NPI 1871980078
$3,635.17
in general payments reported to CMS, 2019-2025
12 companies · $438 in 2025
The $438 reported for 2025 was more than what 76% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,159 · 2020: $113 · 2021: $329 · 2022: $184 · 2023: $636 · 2024: $776 · 2025: $438.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,851.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,850.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,648.16 | 2022-2025 | Ubrelvy, Botox, Qulipta |
| Medtronic USA, INC. | $1,015.39 | 2019 | |
| Allergan, INC. | $557.64 | 2019-2022 | |
| Ucb, INC. | $128.62 | 2023-2025 | Fintepla, Rystiggo, Briviact |
| Emd Serono, INC. | $100.31 | 2023-2024 | Mavenclad |
| Teva Pharmaceuticals USA, INC. | $47.85 | 2023-2024 | Austedo Xr |
| Ferring Pharmaceuticals INC. | $31.94 | 2020 | |
| Argenx US, INC. | $29.15 | 2024 | Vyvgart Hytrulo |
| Sk Life Science, INC. | $23.86 | 2024 | |
| Neurelis, INC. | $23.30 | 2024 | Valtoco |
| Novo Nordisk INC | $17.81 | 2024 | Wegovy |
| Tanabe Pharma America, INC. | $11.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Sukumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.